A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
Clinical trial NCT04280718 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04280718
- Sponsor
- argenx
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-09-18
- Primary completion
- 2027-04-30
- Enrollment
- 229
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.